Nanoparticle Adjuvants Incorporating Haptens Drive Potent Immune Tolerance to Accelerate Hair Regrowth

January 2025 in “ ACS Applied Materials & Interfaces ”

Ni An, Guzailinuer Yasen, Ximu Li, Xianbao Shi, Yongjun Wang, Hongzhuo Liu

From the encyclopedia

mTOR regulator and immunosuppressant used more recently for anti-aging and hair regrowth

autoimmune disorder causing patchy hair loss

Studysummary In this study, a nanoparticle system codelivering diphenylcyclopropenone and rapamycin successfully induced immune tolerance and promoted hair regrowth in a mouse model of alopecia areata, offering a promising new therapeutic strategy for this autoimmune condition.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

This study addresses alopecia areata (AA), an autoimmune condition causing hair loss, by introducing a novel nanoparticle (NP) system that co-delivers diphenylcyclopropenone (DPCP) and rapamycin (RAPA) prodrugs. These NPs are designed to induce immune tolerance and promote hair regeneration. The research demonstrated that the coassembled NPs were stable, efficiently taken up by antigen-presenting cells, and induced dendritic cells to differentiate into tolerogenic phenotypes in vitro. In vivo studies using a mouse model of alopecia showed that these NPs significantly accelerated the transition of hair follicles from the telogen phase to the anagen phase, thereby promoting hair regrowth. This approach offers a promising therapeutic strategy for AA and provides insights into treating autoimmune diseases with unclear autoantigens.

View this study on doi.org →

Discuss this study in the Community →

Research cited in this study

20 / 20 results

research Deciphering the Complex Immunopathogenesis of Alopecia Areata

45 citations , May 2024 in “International Journal of Molecular Sciences”

This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.

Polydopamine Synergizes with Quercetin Nanosystem to Reshape the Perifollicular Microenvironment for Accelerating Hair Regrowth in Androgenetic Alopecia

research Polydopamine Synergizes with Quercetin Nanosystem to Reshape the Perifollicular Microenvironment for Accelerating Hair Regrowth in Androgenetic Alopecia

May 2024 in “Nano letters”

This study developed a quercetin-encapsulated and polydopamine-integrated nanosystem that reshapes the perifollicular microenvironment, showing potential for rescuing hair follicle viability and regenerating hair follicles in androgenic alopecia by scavenging reactive oxygen species and promoting angiogenesis.

research MTOR Signaling in Hair Follicle and Hair Diseases: Recent Progress

September 2023 in “Frontiers in medicine”

This review suggests that the mTOR signaling pathway may play a significant role in hair follicle health by influencing the effects of Vitamin D receptor deficiency, potentially contributing to hair follicle damage and related hair loss conditions.

research Alopecia Areata: Current Treatments and New Directions

57 citations , August 2023 in “American Journal of Clinical Dermatology”

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

research MTORC1 Activity Negatively Regulates Human Hair Follicle Growth and Pigmentation

12 citations , May 2023 in “EMBO reports”

In this study with organ-cultured human scalp hair follicles, high mTORC1 activity correlated with gray/white hair and reduced pigmentation, while inhibiting mTORC1 with rapamycin increased hair growth and pigmentation, suggesting mTORC1 inhibition could be a strategy for treating hair depigmentation and loss.

research The Potential of Regulatory T Cell-Based Therapies for Alopecia Areata

May 2023 in “Frontiers in Immunology”

This article discusses the role of regulatory T cells in alopecia areata, where their deficiency in hair follicles may lead to impaired local immunity and suggests potential therapies like CAR-T reg cells and low-dose IL-2 to alleviate autoimmunity and promote hair regeneration in affected individuals.

research Novel Potential Therapeutic Targets of Alopecia Areata

1 citations , April 2023 in “Frontiers in Immunology”

This review explored recent research on the immune mechanisms and potential therapeutic targets for alopecia areata, highlighting the roles of immune-related cells, autocrine and paracrine signaling, as well as factors like adipose-derived stem cells and gut microbiota in disease pathogenesis.

The Efficacy, Safety, and Recurrence Rate of Diphenylcyclopropenone Topical Immunotherapy for Alopecia Areata: A Systematic Review and Meta-Analysis

research The Efficacy, Safety, and Recurrence Rate of Diphenylcyclopropenone Topical Immunotherapy for Alopecia Areata: A Systematic Review and Meta-Analysis

January 2023 in “Dermatologic therapy”

This study reports that diphenylcyclopropenone topical immunotherapy resulted in any hair regrowth for 69% of patients with alopecia areata, but with common side effects including mild to severe contact dermatitis.

research Topical SCD-153, A 4-Methyl Itaconate Prodrug, For The Treatment Of Alopecia Areata

2 citations , December 2022 in “PNAS nexus”

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

research Aging of Hair Follicle Stem Cells and Their Niches

2 citations , November 2022 in “Journal of Biochemistry and Molecular Biology”

This review discusses how aging affects hair follicle stem cells and their environment, contributing to hair loss, and explores strategies to promote hair regrowth, but reports no new results.

Promotion of Hair Regrowth by Transdermal Dissolvable Microneedles Loaded with Rapamycin and Epigallocatechin Gallate Nanoparticles

research Promotion of Hair Regrowth by Transdermal Dissolvable Microneedles Loaded with Rapamycin and Epigallocatechin Gallate Nanoparticles

7 citations , July 2022 in “Pharmaceutics”

This study found that a dissolvable microneedle device delivering rapamycin and epigallocatechin gallate nanoparticles significantly enhanced hair regrowth in C57BL/6 mice within 7 days, demonstrating increased hair shaft growth and follicle density with minimal inflammation compared to untreated mice.

research Autoantigen Discovery in the Hair Loss Disorder, Alopecia Areata: Implications of Post-Translational Modifications

11 citations , June 2022 in “Frontiers in immunology”

This review discusses the challenges in identifying specific hair follicle antigens involved in initiating alopecia areata and highlights the need for further research to understand its etiopathogenesis, reporting no new results.

research Minoxidil-Loaded Hyaluronic Acid Dissolving Microneedles to Alleviate Hair Loss in an Alopecia Animal Model

12 citations , February 2022 in “Acta Biomaterialia”

In this study, researchers found that dissolving microneedles made with hyaluronic acid enhanced the effectiveness of minoxidil in reducing hair loss and promoting hair growth in alopecia-affected mice more effectively than topical minoxidil alone, while using only 10% of the drug amount.

research Alopecia Areata: An Autoimmune Disease of Multiple Players

31 citations , July 2021 in “ImmunoTargets and therapy”

This review compiles current evidence on the molecular mechanisms, etiologies, and targeted immunotherapies for alopecia areata and reports no new experimental results, emphasizing the need for further research to manage the disease.

research Application of Topical Immunotherapy in the Treatment of Alopecia Areata: A Review and Update

20 citations , March 2021 in “Drug design, development and therapy”

This review summarizes the pharmacology, mechanisms, and clinical efficacy of topical immunotherapy for alopecia areata but reports no new clinical results.

research Alopecia Areata: A Review on Diagnosis, Immunological Etiopathogenesis, and Treatment Options

56 citations , January 2021 in “Clinical and Experimental Medicine”

This review highlights the challenges in treating alopecia areata, noting that current therapies often lead to relapse and have uncertain long-term effectiveness; it also points to potential future treatments such as JAK-STAT inhibitors and PRP.

research Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata

134 citations , July 2020 in “Experimental dermatology”

This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.

research Clinical Efficacy of Diphenylcyclopropenone in Alopecia Areata: Retrospective Data Analysis of 50 Patients

41 citations , November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings”

This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.

research Trichohyalin Is a Potential Major Autoantigen in Human Alopecia Areata

66 citations , July 2010 in “Journal of Proteome Research”

This study suggests that an immune response to trichohyalin and keratin 16 may contribute to the pathogenesis of alopecia areata.

research Effects of Immunosuppressive Peptidyl-Prolyl Cis-Trans Isomerase (PPIase) Inhibitors, Cyclosporin A, FK506, Ascomycin, and Rapamycin, on Hair Growth Initiation in Mice: Immunosuppression Is Not Required for New Hair Growth

20 citations , January 1995 in “Journal of Dermatological Science”

This study found that topical application of cyclosporin A and FK506 induces new hair growth in mice, while ascomycin and rapamycin do not, suggesting hair induction is not due to immunosuppression.